NASDAQ:KALV - Kalvista Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$24.85 -0.54 (-2.13 %)
(As of 04/18/2019 10:28 AM ET)
Previous Close$25.39
Today's Range$24.84 - $25.84
52-Week Range$7.73 - $34.92
Volume5,665 shs
Average Volume120,457 shs
Market Capitalization$428.59 million
P/E RatioN/A
Dividend YieldN/A
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, an intravitreally administered plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE. The company is headquartered in Cambridge, Massachusetts.

Receive KALV News and Ratings via Email

Sign-up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:KALV



Sales & Book Value

Annual Sales$8.39 million
Book Value$2.52 per share


Net Income$-15,800,000.00


Market Cap$428.59 million
Next Earnings Date7/30/2019 (Estimated)
OptionableNot Optionable

Kalvista Pharmaceuticals (NASDAQ:KALV) Frequently Asked Questions

What is Kalvista Pharmaceuticals' stock symbol?

Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

How were Kalvista Pharmaceuticals' earnings last quarter?

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) announced its earnings results on Thursday, March, 14th. The specialty pharmaceutical company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.22. The specialty pharmaceutical company earned $3.89 million during the quarter, compared to analysts' expectations of $3.97 million. Kalvista Pharmaceuticals had a negative net margin of 70.08% and a negative return on equity of 19.12%. View Kalvista Pharmaceuticals' Earnings History.

When is Kalvista Pharmaceuticals' next earnings date?

Kalvista Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, July 30th 2019. View Earnings Estimates for Kalvista Pharmaceuticals.

What price target have analysts set for KALV?

6 analysts have issued 12-month price targets for Kalvista Pharmaceuticals' stock. Their forecasts range from $20.00 to $35.00. On average, they anticipate Kalvista Pharmaceuticals' stock price to reach $29.25 in the next year. This suggests a possible upside of 17.7% from the stock's current price. View Analyst Price Targets for Kalvista Pharmaceuticals.

What is the consensus analysts' recommendation for Kalvista Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kalvista Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kalvista Pharmaceuticals.

What are Wall Street analysts saying about Kalvista Pharmaceuticals stock?

Here are some recent quotes from research analysts about Kalvista Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which are in clinical stage. KalVista Pharmaceuticals, Inc., formerly known as Carbylan Therapeutics, Inc., is headquartered in Cambridge, United States. " (3/2/2019)
  • 2. BTIG Research analysts commented, "Another Beat-and-Raise; Reiterate Buy and $260 PT TMO kicked off 2018 on a strong note, with 7% organic revenue growth (against 4% growth in 1Q17) and 20% EPS growth (upside from guidance largely driven by higher organic growth, and less so from more favorable FX), handily beating consensus expectations. Full year guidance was raised: 1) on the top, to reflect (roughly in equal parts of) better organic revenue growth (5% from 4-5% prior), greater Patheon acquisition contribution, and more favorable FX; and 2) on the bottom, stronger 1Q operational performance and more favorable FX, partially offset by small dilution from a recent bolt-on. Strong performance was broad-based, although standouts in the quarter include the biopharma customer segment (+10% y/y), China (high-teens growth), and Analytical Instruments (+13% organic growth; strength across FEI, chromatography / MS, chemical analysis). While TMO has a strong financial performance track record, we think the company is currently better positioned than ever to capitalize on a relatively strong end market environment (e.g., biopharma, industrial) and take market share to drive top line growth, continue to execute on operational efficiency (e.g., Patheon acquisition synergy targets tracking ahead of expectations), and maximize capital deployment opportunities (3.8x leverage ratio at quarter-end vs. 3.75x estimated year-end average; ~$500mm share buyback targeted for 2H; active M&A pipeline; rising interest rates already factored into longer-term forecasts and strategic planning). Our PT gets valuation closer to the peer average on a forward P/E basis." (4/29/2018)

Has Kalvista Pharmaceuticals been receiving favorable news coverage?

Media coverage about KALV stock has trended somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kalvista Pharmaceuticals earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave news coverage about the specialty pharmaceutical company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days.

Who are some of Kalvista Pharmaceuticals' key competitors?

What other stocks do shareholders of Kalvista Pharmaceuticals own?

Who are Kalvista Pharmaceuticals' key executives?

Kalvista Pharmaceuticals' management team includes the folowing people:
  • Mr. Thomas Andrew Crockett, CEO & Director (Age 44)
  • Mr. Benjamin L. Palleiko, Chief Financial Officer (Age 53)
  • Mr. Andreas Maetzel M.D., M.Sc., Ph.D., Sr. VP of Medical (Age 56)
  • Mr. John B. McKune, VP of Fin. (Age 43)
  • Dr. Edward P. Feener, Chief Scientific Officer (Age 59)

Who are Kalvista Pharmaceuticals' major shareholders?

Kalvista Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Tibra Equities Europe Ltd (0.15%). Company insiders that own Kalvista Pharmaceuticals stock include Albert Cha, Andreas Maetzel, Christopher Yea, Edward P Feener, Holdings A/S Novo, Life Sciences Fund Iv (Gp) Sv, Rajeev M Shah, Svlsf Iv, Llc, Thomas Andrew Crockett and Venrock Healthcare Capital Par. View Institutional Ownership Trends for Kalvista Pharmaceuticals.

Which institutional investors are buying Kalvista Pharmaceuticals stock?

KALV stock was purchased by a variety of institutional investors in the last quarter, including Tibra Equities Europe Ltd. Company insiders that have bought Kalvista Pharmaceuticals stock in the last two years include Albert Cha and Rajeev M Shah. View Insider Buying and Selling for Kalvista Pharmaceuticals.

How do I buy shares of Kalvista Pharmaceuticals?

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kalvista Pharmaceuticals' stock price today?

One share of KALV stock can currently be purchased for approximately $24.85.

How big of a company is Kalvista Pharmaceuticals?

Kalvista Pharmaceuticals has a market capitalization of $428.59 million and generates $8.39 million in revenue each year. The specialty pharmaceutical company earns $-15,800,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis. Kalvista Pharmaceuticals employs 33 workers across the globe.

What is Kalvista Pharmaceuticals' official website?

The official website for Kalvista Pharmaceuticals is

How can I contact Kalvista Pharmaceuticals?

Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]

MarketBeat Community Rating for Kalvista Pharmaceuticals (NASDAQ KALV)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  193 (Vote Outperform)
Underperform Votes:  117 (Vote Underperform)
Total Votes:  310
MarketBeat's community ratings are surveys of what our community members think about Kalvista Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/18/2019 by Staff

Featured Article: What are retained earnings?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel